Læknablaðið : fylgirit - 01.05.1978, Qupperneq 50

Læknablaðið : fylgirit - 01.05.1978, Qupperneq 50
Anna-Liisa Mákelá and Jarkko Haapasaari Department of Paediatrics, Turku University Hospital, Turku, Finland GOLD THERAPY AND ITS SIDE EFFECTS IN CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS The toxicity of chrysotherapy and the role of serum gold concentrations in the adjustment of gold therapy has been widely discussed in recent years. In 1973 Lorber and coworkers pointed out the importance of monitoring the serum gold values. According to them, the beneficial response to chrysotherapy is more likely to be sustained if the serum gold concentration is maintained at or abcrve 300 ug per cent, corre- sponding to 15 umol/1. (1) In Figure 1, by Lorber and coworkers the serum gold levels in patients receiving conventional chrysotherapy with monthly gold injections are compared with those achieved by adjusted regimen with weekly gold injections. A sharp increase in serum gold levels is seen within 2 hours after gold injections. Thereafter, there is a progressive fall during the ensuing week or weeks. With 0-212 3 4 5 6 7 h Days afler injection Adjusled therapy Conventional _ therapy Fig. 1 Serum gold levels in patients receiving conventional chrysotherapy with monthly gold injections are compared with those achieved by adjusted regimen with weekly gold injections. (Lorber et al.: Ann rheum Dis 32:133, 1973) individually adjusted therapy the serum gold level is maintained above 300 ug per cent. Concerning child patients I have not found any earlier reports on serum gold levels with differ- ent treatment schedules. In the treatment of children with juvenile rheumatoid arthritis an empiric schedule of chrysotherapy has been used according to which a single dose of Myocrisin should not exceed the amount of 1 mg/kg of body weight and never be more than 50 mg. The injections are given once a week for at least 10 weeks: after that, the intervals may be prolonged, from fourteen days to one month. At our clinic, 125 children with JRA have been treated by this regimen during the past 10-15 years. When analysing this material, side effects of the gold treatment were observed in 66 cases (in 53 per cent of the patients), in several cases various side effects at the same time. The age of the children at the beginning of the treatment ranged between 3 and 15 years. The frequency of the side effects increased very clearly with increasing age of the children. (Table 1). The quality of complications in different age groups is seen in Table 2. The percentile amount of proteinuria increased with increasing age. The total dose of gold exceeded 1 gr in 35 cases, 2 gr in 10 cases and 3 gr in 3 cases in the whole material. Neither the duration of the treatment nor the total dose of gold in milligrams accounts for the higher frequency of side effects in older age groups. (Table 3) The various age groups did not display any mutual differences in the percentile amounts of complications in the groups whose total dose of gold exceeded 1000 mg. The frequency of different side effects, calcu- lated as percentages from the total number of patients is seen in Table 4. The most common was proteinuria, observed in 36% of the cases, haematuria was observed in 7% of the cases, eosinophilia in 11% and dermatitis in 1C%. 48
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140
Qupperneq 141
Qupperneq 142
Qupperneq 143
Qupperneq 144
Qupperneq 145
Qupperneq 146
Qupperneq 147
Qupperneq 148
Qupperneq 149
Qupperneq 150
Qupperneq 151
Qupperneq 152
Qupperneq 153
Qupperneq 154
Qupperneq 155
Qupperneq 156
Qupperneq 157
Qupperneq 158

x

Læknablaðið : fylgirit

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.